预约演示

Incyte whittles down pipeline, scrapping 6 R&D programs

2023-05-02

临床1期临床2期上市批准临床3期临床终止

Incyte's pipeline cuts will allow the pharma to funnel resources to “programs that can have a high impact for patients and for Incyte," according to CEO Hervé Hoppenot.

Incyte is whittling down its R&D pipeline, scrapping six discovery programs—one in a rare form of anemia and five in various caIncyteto focus on eight remaining programs.

Incytekafi maker’s remaining R&D programs “have high potential,” Incyte CEO Hervé Hoppenot said inanemia 2 release. The pipelcancersm will allow the pharma to funnel its resources to “programs that can have a high impact for patients and for Incyte."

The company has ended phase 3 work on a small molecule PI3K inhibIncytenown as parsaclisib—in warm autoimmune hemolytic anemia, citing the “challenging regulatory landscape associated with the PI3K class.” While several PI3K inhibitors have mIncyte to snag FDA approval, the drug class has been frequently tied to serious or even fatal side effects. Last year, the FDA lost confidence in the safety profile of PI3K inhibitors for blood cancers after data from six randomized clinical trials indicated that four marketed PI3K inhibitors may shorten blood cancer patients’ life expectancy because of their toxicity. Since then, the agency said it would put the meds under a more stringent regulatory scope.

Incyte’s parsaclisib had also been assessed in a phase PI3Kial as a combo treatparsaclisibide the pharma’s apphemolytic anemiator Jakafi for certain cancers. However, the pharma’s first effort PI3Kuilding a better JakafiPI3Kimen ended in failure after an inFDAendent data monitoring committee found it was on course to miss the primary endpoint of reducing spleen vFDAme in patients with bone marrow cancer myePI3Kbrosis, and the blood cancerscontinued.PI3K blood cancer

Incyte haparsaclisibd development of its adenosine program, which includes four separate assets. First on the list iJAK inhibitor Jakafi JAKNCB106385, which was being asscancersn two separate phase 1 trials among patients with advancedJakafi tumors. One of those trials also evaluated INCA00186, which is being discontinued, alongside anti-GITR antibody INCAGN1876 in various cancers and INCB81776 in advancedbone marrow cancer myelofibrosis programs were discontinued based on early efficacy data, according to Incyte’s release.

IncyteIncyte continues to expand the reach of pemazyre—the first FDA-approved drug designed to specifically treat bileINCB106385er—in non-U.S. countries, the pharma has ended a phase 2 clinical trial dubbedadvanced solid tumorsesting out the drug in non-small cellINCA00186cer.INCAGN1876 cancers INCB81776 advanced malignancies adenosine Incyte

So whaIncyteins?pemazyre bile duct cancer non-small cell lung cancer

One of the eight programs the company is zooming in on is INCB123667, a CDK2 inhibitor being studied in a phase 1 trial for patients with advanced malignancies. Another of the surviving programs is INCA33890, a bispecific antibody that has shown anti-tumor effects in preclinical studies. Alongside other discovery programs, Incyte continues to work to expand labels for its approved drugs.

Despite the R&D overhaul, the drug developer still seems tINCB123667tingCDK2 inhibitor CDK2new science for its pipeline. Last month, Incyte paid out $7 madvanced malignanciesotheryx’s platform to identify and initINCA33890elop molecular glue degraders for “multiple tumorrically undruggable oncology targets.” The deal gives Biotheryx the cIncyteto make another $6 million in R&D funding and up to $347 million in milestone payments.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构